<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00572182</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000578114</org_study_id>
    <secondary_id>U01CA081457</secondary_id>
    <secondary_id>PBTC-024</secondary_id>
    <secondary_id>NCI-09-C-0112</secondary_id>
    <nct_id>NCT00572182</nct_id>
    <nct_alias>NCT00923208</nct_alias>
  </id_info>
  <brief_title>MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer</brief_title>
  <official_title>A Phase I Study of MK-0752 in Pediatric Patients With Recurrent or Refractory CNS Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pediatric Brain Tumor Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Pediatric Brain Tumor Consortium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: MK0752 may stop the growth of tumor cells by blocking some of the enzymes needed&#xD;
      for cell growth.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of MK0752 in treating&#xD;
      young patients with recurrent or refractory CNS cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To estimate the maximum tolerated dose (MTD) and recommended phase II dose of MK0752&#xD;
           administered for 3 consecutive days of every 7 days in 28 day courses to young patients&#xD;
           with recurrent or refractory CNS malignancies (Dosing regimen 1 - closed to accrual&#xD;
           2/23/2010).&#xD;
&#xD;
        -  To estimate the MTD and recommend a phase II dose of MK0752 administered once weekly in&#xD;
           28 day courses to young patients with recurrent or refractory CNS malignancies (Dosing&#xD;
           regimen 2).&#xD;
&#xD;
        -  To compared the MK0752 systemic exposure attained with each dosage level on the&#xD;
           different dosing regimens.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To characterize the pharmacokinetics of MK0752.&#xD;
&#xD;
        -  To document and describe toxicities associated with MK0752.&#xD;
&#xD;
        -  To preliminarily define the antitumor activity of MK0752 within the confines of a phase&#xD;
           I setting.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study.&#xD;
&#xD;
      Patients receive oral MK0752 once daily on days 1-3, 8-10, 15-17, and 22-24 (dosing regimen 1&#xD;
      - closed to accrual 2/23/2010) or days 1, 8, 15, and 22 (dosing regimen 2). Treatment repeats&#xD;
      every 28 days for up to 6 courses in the absence of disease progression or unacceptable&#xD;
      toxicity. Treatment may be extended up to 19 courses if the patient is benefitting from the&#xD;
      treatment.&#xD;
&#xD;
      Patients undergo blood sample collection periodically for pharmacokinetic studies.&#xD;
&#xD;
      After completion of study treatment, patients are followed for 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This Phase I study was permanently closed to patient accrual on February 23, 2011, due to the&#xD;
    discontinuation of support from MERCK.&#xD;
  </why_stopped>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>First 28 days of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MK0752 systemic exposure</measure>
    <time_frame>Day 1 of course 1</time_frame>
    <description>Serial blood samples for pharmacokinetic studies of MK-0752 will be collected with the first dose of course 1 at pre-specified times.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Day 1 of course 1</time_frame>
    <description>Serial blood samples for pharmacokinetic studies of MK-0752 will be collected with the first dose of course 1 at pre-specified times.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>From day 1 of treatment until off study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>End of courses 2, 4, 6 and at the end of treatment</time_frame>
    <description>Brain imaging to assess tumor response to the treatment is performed at baseline, at the end of courses 2, 4, 6 and at the end of therapy.</description>
  </secondary_outcome>
  <enrollment type="Actual">33</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-0752</intervention_name>
    <description>This is a dose escalation study. Patients may receive 150, 200, 260 or 325 mg/m2 orally for 3 consecutive days of every 7 days for 28 days (dosing regimen 1 - closed to accrual 2/23/2010) or 800, 1000, 1400, or 1800 mg/m2 orally once weekly for 28 days (1 course). In the absence of unacceptable toxicity or disease progression, treatment may continue for 6 courses.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed primary CNS tumor&#xD;
&#xD;
               -  Patients with intrinsic brain stem tumors do not require histologic verification,&#xD;
                  but must have radiographic evidence of progression&#xD;
&#xD;
          -  Recurrent disease or refractory to standard therapy&#xD;
&#xD;
          -  No histologically benign brain tumors (e.g., low-grade glioma)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status (PS) or Lansky PS 60-100%&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/μL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/μL (unsupported)&#xD;
&#xD;
          -  Hemoglobin ≥ 8 g/dL (RBC transfusions allowed)&#xD;
&#xD;
          -  Creatinine clearance OR glomerular filtration rate ≥ 70 mL/min OR serum creatinine&#xD;
             based on age as follows:&#xD;
&#xD;
               -  0.8 mg/dL (≤ 5 years of age)&#xD;
&#xD;
               -  1.0 mg/dL (&gt; 5 to ≤ 10 years of age)&#xD;
&#xD;
               -  1.2 mg/dL (&gt; 10 to ≤ 15 years of age)&#xD;
&#xD;
               -  1.5 mg/dL (&gt; 15 years of age)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN) for age&#xD;
&#xD;
          -  ALT ≤ 2.5 times ULN for age&#xD;
&#xD;
          -  Albumin ≥ 2.5 g/dL&#xD;
&#xD;
          -  Sodium, potassium, magnesium, and calcium normal&#xD;
&#xD;
          -  Patients with neurological deficits are eligible provided these deficits are stable&#xD;
             for ≥ 2 weeks prior to study registration&#xD;
&#xD;
          -  No clinically significant systemic illness (e.g., serious infection or significant&#xD;
             cardiac, pulmonary, hepatic, or other organ dysfunction) that would compromise the&#xD;
             patient's ability to tolerate study therapy or would likely interfere with the study&#xD;
             procedures or results&#xD;
&#xD;
          -  No known hypersensitivity to MK0752&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Recovered from the acute toxic effects of all prior therapy&#xD;
&#xD;
          -  At least 3 weeks since prior myelosuppressive anticancer chemotherapy (6 weeks for&#xD;
             nitrosoureas)&#xD;
&#xD;
          -  At least 7 days since prior investigational or biologic agents&#xD;
&#xD;
               -  At least 3 weeks since prior investigational or biologic agents that have a&#xD;
                  prolonged half-life or for which the patient has experienced ≥ grade 2&#xD;
                  myelosuppression in the treatment course preceding discontinuation of therapy&#xD;
&#xD;
          -  At least 3 half lives since prior monoclonal antibody therapy&#xD;
&#xD;
          -  At least 6 months since prior total body irradiation or craniospinal radiotherapy&#xD;
&#xD;
          -  At least 6 weeks since other prior substantial bone marrow irradiation&#xD;
&#xD;
          -  At least 2 weeks since prior local palliative radiotherapy (small volume)&#xD;
&#xD;
          -  At least 6 months since prior allogeneic bone marrow transplantation (BMT)&#xD;
&#xD;
               -  No evidence of active graft versus host disease&#xD;
&#xD;
          -  At least 3 months since prior autologous BMT or stem cell transplantation&#xD;
&#xD;
          -  At least 7 days since prior hematopoietic growth factors (filgrastim [G-CSF],&#xD;
             sargramostim [GM-CSF], or erythropoietin) (14 days for long-acting formulations)&#xD;
&#xD;
          -  No prior MK0752&#xD;
&#xD;
          -  No concurrent enzyme-inducing anticonvulsant drugs (EIACDs)&#xD;
&#xD;
          -  No other concurrent anticancer or investigational drug therapy&#xD;
&#xD;
          -  Concurrent dexamethasone allowed provided patient is on a stable or decreasing dose&#xD;
             for ≥ 2 weeks prior to study registration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maryam Fouladi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital - Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NCI - Pediatric Oncology Branch</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dan L. Duncan Cancer Center at Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>December 11, 2007</study_first_submitted>
  <study_first_submitted_qc>December 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2007</study_first_posted>
  <last_update_submitted>March 2, 2012</last_update_submitted>
  <last_update_submitted_qc>March 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent childhood brain stem glioma</keyword>
  <keyword>childhood central nervous system germ cell tumor</keyword>
  <keyword>recurrent childhood cerebellar astrocytoma</keyword>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <keyword>childhood high-grade cerebral astrocytoma</keyword>
  <keyword>childhood choroid plexus tumor</keyword>
  <keyword>childhood craniopharyngioma</keyword>
  <keyword>recurrent childhood ependymoma</keyword>
  <keyword>recurrent childhood medulloblastoma</keyword>
  <keyword>childhood oligodendroglioma</keyword>
  <keyword>recurrent childhood pineoblastoma</keyword>
  <keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>childhood atypical teratoid/rhabdoid tumor</keyword>
  <keyword>childhood spinal cord neoplasm</keyword>
  <keyword>childhood infratentorial ependymoma</keyword>
  <keyword>childhood supratentorial ependymoma</keyword>
  <keyword>recurrent childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>childhood grade III meningioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

